SANTA CRUZ BIOTECHNOLOGY, INC.

Vaccinia Virus (TV46): sc-52302

SANTA CRUZ BIOTECHNOLOGY

The Power to Question

BACKGROUND

Vaccinia Virus belongs to the poxvirus family of viruses. It contains double stranded DNA and was used as a vaccine to eradicate the smallpox disease. Fusion protein plays an important role in the entry of intracellular enveloped virus (IEV) into cells. In Vaccinia Virus, the fusion process is attributed to the action of a protein which is encoded by the Vaccinia Virus A27L gene. This protein plays an important role in the biology of the virus, acting in virus-to-cell and cell-to-cell fusions. The protein is required for the microtubule-dependent transport of intracellular mature virus particles and for the process of envelopment that leads to IEV formation. The N-terminus of this protein recognizes heparan sulfate on the cell surface and interacts with the negative charges of sulfates of glycosaminoglycans (GAGs). Therefore, antibodies that recognize this protein are able to neutralize Vaccinia Virus infection and to identify other viral and cellular proteins which participate in the Vaccinia Virus entry process.

REFERENCES

1. Rodriguez, D., Risco, C., Rodriguez, J.R., Carrascosa, J.L. and Esteban, M. 1996. Inducible expression of the Vaccinia Virus A17L gene provides a synchronized system to monitor sorting of viral proteins during morphogenesis. J. Virol. 70: 7641-7653.
2. Vazquez, M.I., Rivas, G., Cregut, D., Serrano, L. and Esteban, M. 1998. The Vaccinia Virus 14-kilodalton (A27L) fusion protein forms a triple coiled-coil structure and interacts with the 21-kilodalton (A17L) virus membrane protein through a C-terminal α-helix. J. Virol. 72: 10126-10137.
3. Vazquez, M.I. and Esteban, M. 1999. Identification of functional domains in the 14-kilodalton envelope protein (A27L) of Vaccinia Virus. J. Virol. 73: 9098-9109.
4. Sanderson, C.M., Hollinshead, M. and Smith, G.L. 2000. The Vaccinia Virus A27L protein is needed for the microtubule-dependent transport of intracellular mature virus particles. J. Gen. Virol. 81: 47-58.
5. Matsui, M., Moriya, O., Yoshimoto, T. and Akatsuka, T. 2005. T-bet is required for protection against Vaccinia Virus infection. J. Virol. 79: 12798-12806.
6. Roper, R.L. 2005. Characterization of the Vaccinia Virus A35R protein and its role in virulence. J. Virol. 80: 306-313.
7. Okeke, M.I., Nilssen, O. and Traavik, T. 2006. Modified Vaccinia Virus Ankara multiplies in rat IEC-6 cells and limited production of mature virions occurs in other mammalian cell lines. J. Gen. Virol. 87: 21-27.
8. Moerdyk, M.J., Byrd, C.M. and Hruby, D.E. 2006. Analysis of Vaccinia Virus temperat functional domains. Virol. J. 3: 64.
9. Pillay, N.S., Kellaway, L.A. and Kotwal, G.J. 2006. Administration of Vaccinia Virus complement control protein shows significant cognitive improvement in a mild injury model. Ann. N.Y. Acad. Sci. 1056: 450-461.

SOURCE

Vaccinia Virus (TV46) is a mouse monoclonal antibody raised against a tissue/cell preparation of Vaccinia Virus.

PRODUCT

Each vial contains 100 µg IgG_{2a} in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

Vaccinia Virus (TV46) is recommended for detection of Vaccinia Virus by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000).

Molecular Weight of Vaccinia Virus: 14 kDa.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.